CADTH Canadian Drug Expert Committee recommendation : indication : for the symptomatic treatment of lower limb spasticity (LLS) in pediatric patients two years of age and older : AbobotulinumtoxinA (Dysport therapeutic--Ipsen Biopharmaceuticals Canada, Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Muscles--Diseases.

Muscles.

Cost effectiveness.

Outcome assessment (Medical care).

Physical Description:

1 online resource (8 pages)

Edition:

Version: Final.

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018.

Summary:

AbobotulinumtoxinA (aboBoNTA) is a botulinum toxin that blocks nerve activity in the muscles, causing a temporary reduction in muscle activity. The recommended starting dosage of aboBoNTA for pediatric patients with lower-limb spasticity (LLS) is 10 U/kg to 15 U/kg for unilateral lower-limb injections, or 20 U/kg to 30 U/kg for bilateral lower-limb injections per treatment session. Treatment can be administered to multiple sites of muscles within the lower limb. If the treatment effect from the first dose diminishes over time, patients can be re-treated after a period of at least 12 weeks. The manufacturer submitted a cost-utility analysis comparing aboBoNTA with onabotulinumtoxinA (onaBoNTA) in pediatric patients two years of age or older with unilateral or bilateral LLS.

Notes:

Description based on publisher supplied metadata and other sources.